Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update
Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update
复制标题
DOI：
10.1111/hepr.13504
复制
发表时间：
2020-07-15
影响因子：
4.2
通讯作者：
Yotsuyanagi, Hiroshi
中科院分区：
文献类型：
--
作者：
Ando, Ryoichi;Asahina, Yasuhiro;Yotsuyanagi, Hiroshi
日本肝病学会设立的肝炎管理指南起草委员会于2013年出版了B型肝炎管理指南的第一版（2014年出版了第一个英文版），此后随着新药的上市，一直在出版指南的更新，最新的日文原版是3.1版。在此，起草委员会发布第二个英文版本，其中包含自2014年发布第一个英文版本以来所做的所有更改。本2019年版本涵盖：（i）核苷（酸）类似物，富马酸替诺福韦二异丙酯和替诺福韦艾拉酚胺;（ii）反映这些药物新可用性的耐药B型肝炎病毒的治疗建议和管理更新;以及（iii）每次更新有关B型肝炎病毒再激活的新信息。最新更新还包含有关治疗目标、治疗适应症和核苷（酸）类似物治疗停止的信息，其中大部分内容已在第一版中涵盖。
The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs become available, with the latest original Japanese version being Version 3.1. Herein, the Drafting Committee publishes the second English version that contains all the changes made since the first English version of the guidelines was published in 2014. This 2019 version covers: (i) the nucleos(t)ide analogs, tenofovir disoproxil fumarate and tenofovir alafenamide; (ii) updates to treatment recommendations and management of drug-resistant hepatitis B virus that reflect the new availability of these drugs; and (iii) new information about hepatitis B virus reactivation with each update. This latest update also contains information about treatment goals, indications for treatment and cessation of nucleos(t)ide analog therapy, most of which were covered by the first version.